Zachary Bessette

DocwireNews

Combination amivantamab plus chemotherapy shows “encouraging” and durable antitumor activity, along was a manageable safety profile, for anti-EGFR-naïve RAS/RAF wild-type metastatic colorectal cancer (mCRC), according to results of the open-label phase Ib/II OrigAMI-1 study presented at the European Society for Medical Oncology Congress 2024.
Amivantamab is an EGFR-MET bispecific antibody with immune cell-directing activity. It has demonstrated promising monotherapy activity in patients with relapsed or refractory mCRC. While standard-of-care therapy for RAS/RAF wild-type mCRC is 5-FU-based doublet or triplet chemotherapy (FOLFOX or FOLFIRI) with or without biologics, amivantamab may offer improved outcomes with manageable safety due to its unique mechanism of action.
Dr. Filippo Pietrantonio and colleagues designed the OrigAMI-1 study to assess the safety and efficacy of amivantamab (1,050 mg) plus mFOLFOX6 or FOLFIRI in anti-EGFR-naïve RAS/RAF wild-type mCRC. A total of 44 patients were sampled with confirmed wild-type for KRAS, NRAS, BRAF, and EGFR ectodomain by ctDNA testing, without ERBB2/HER2 amplification. Patients had received no more than one prior line of therapy in the metastatic setting.
As of April 8, 2024, 21 patients received amivantamab plus FOLFOX and 23 received amivantamab plus FOLFIRI at a median follow-up of 3.9 months and 4.4 months, respectively. Dr. Pietrantonio and colleagues reported that the best timepoint response rate was 63% and 48%, respectively. The median duration of response among confirmed responders was not estimable and 6.5 months, respectively.
Furthermore, the researchers noted that rash and neutropenia were the most frequent treatment-emergent adverse events and no new safety signals were observed.
“Amivantamab plus chemotherapy demonstrated encouraging, durable antitumor activity and a manageable safety profile in anti-EGFR-naïve RAS/RAF wild-type mCRC,” they concluded.

Jordana Jampel

Potential Groundbreaking Biomarker for Immunotherapy Assessment Across Breast Cancer

Breast Cancer

Brandon Twyford

CHMP Recommends Tislelizumab for First-Line Therapy in Advanced Gastric and Esophageal Cancers

Gastric Cancer

Cecilia Brown

Rebekah Kaufman

Lauren Kiel

Researchers Share Insights From Lung Cancer and Pregnancy Registry

WCLC 2024

Latest News

OrigAMI-1: Amivantamab Plus FOLFOX or FOLFIRI for Metastatic CRC

Colorectal Cancer

Amivantamab plus chemo shows encouraging and durable antitumor activity for anti-EGFR-naïve RAS/RAF wild-type mCRC.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Gastroesophageal Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Career Center

Expert Interviews

Subscribe